Role of aggressive surgical cytoreduction in advanced ovarian cancer.
10.3802/jgo.2015.26.4.336
- Author:
Suk Joon CHANG
1
;
Robert E BRISTOW
;
Dennis S CHI
;
William A CLIBY
Author Information
1. Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Korea. drchang@ajou.ac.kr
- Publication Type:Review
- Keywords:
Cytoreduction Surgical Procedures;
Neoplasm, Residual;
Ovarian Neoplasms
- MeSH:
Cytoreduction Surgical Procedures/*methods;
Evidence-Based Medicine;
Female;
Humans;
Neoplasm, Residual/surgery;
Observer Variation;
Ovarian Neoplasms/*surgery;
Practice Patterns, Physicians';
Randomized Controlled Trials as Topic;
Retrospective Studies
- From:Journal of Gynecologic Oncology
2015;26(4):336-342
- CountryRepublic of Korea
- Language:English
-
Abstract:
Ovarian cancer is the eighth most frequent cancer in women and is the most lethal gynecologic malignancy worldwide. The majority of ovarian cancer patients are newly diagnosed presenting with advanced-stage disease. Primary cytoreductive surgery and adjuvant taxane- and platinum-based combination chemotherapy are the standard treatment for advanced ovarian cancer. A number of studies have consistently shown that successful cytoreductive surgery and the resultant minimal residual disease are significantly associated with survival in patients with this disease. Much has been written and even more debated regarding the competing perspectives of biology of ovarian cancer versus the value of aggressive surgical resection. This review will focus on the current evidences and outcomes supporting the positive impact of aggressive surgical effort on survival in the primary management of ovarian cancer.
